In Brief: Baxter/Vimrx
This article was originally published in The Gray Sheet
Executive Summary
Baxter/Vimrx: Firms ink definitive agreement whereby Vimrx Pharmaceuticals and Baxter's Immunotherapy Division will merge to create a new cell therapy company to market cell selection systems, such as Baxter's Isolex 300SA -- a premarket approval application for which currently is pending at FDA -- and Baxter's Isolex 300i. Both systems are marketed in Europe. As outlined in the firms' June 12 letter of intent ("The Gray Sheet" June 16, I&W-7), Vimrx will control 85% of the new entity in exchange for convertible preferred shares with a nominal value of $40 mil. and 11 mil. Vimrx common shares. Baxter will contribute $30 mil. to the company for initial operating funds, a figure $10 mil. larger than the amount Baxter had reported in June. As previously announced, Vimrx will provide $10 mil. in initial funding for the company...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.